Biologics in allergic rhinitis

Basit Öğe Kaydı
dc.authoridMuluk, Nuray Bayar/0000-0003-3602-9289
dc.contributor.authorMuluk, Nuray Bayar
dc.contributor.authorCingi, C.
dc.date.accessioned2025-01-21T16:36:12Z
dc.date.available2025-01-21T16:36:12Z
dc.date.issued2023
dc.departmentKırıkkale Üniversitesi
dc.description.abstractThis paper aims to review biologics in allergic rhinitis (AR). Biologic agents of Omalizumab, Dupilumab, Mepolizumab, Reslizumab, and Benralizumab are reviewed in detail. The search is performed in Pubmed, Google, Google Scholar and EBSCO Academic Search Ultimate (EKUAL) database of Kirikkale University Library from 2021 to 2000, and randomized and/or placebo-controlled studies, review papers, meta-analysis, and reports are taken into consideration. The search was performed with the keywords of allergic rhinitis, biologics, biologic agents, Omalizumab, Dupilumab, Mepolizumab, Reslizumab, Benralizumab, Anti IgE, Anti-IL-4/IL-13, Anti IL-5. Search is also performed in the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) web systems. Biological agents such as monoclonal antibodies (MAb) in treatment are called biological therapy or biotherapy. Omalizumab is a humanized Anti-Ig Emonoclonal antibody. Omalizumab treatment improved the Daily Nasal Rescue Medication Score (DNSSS) and decreased the use of antiallergic drugs in seasonal and perennial AR and rhino-conjunctivitis. Omalizumab is also used in specific immunotherapy patients with allergic rhinitis and reduced allergic reactions associated with allergen immunotherapy, such as anaphylaxis. Dupilumab is an Anti-IL-4/IL-13 biologic agent. Dupilumab treatment significantly improved sino-nasal Outcome Test (SNOT-22) total scores in perennial allergic rhinitis. Anti-IL-5 monoclonal antibodies of Mepolizumab, Reslizumab Benralizumab reduce the number of eosinophils in the blood and tissue, corticosteroid addiction and asthma attacks are reduced, and their use in the treatment of severe eosinophilic asthma has been approved. Biologics, especially Omalizumab, and Dupilumab, may be used more in allergic rhinitis.
dc.identifier.endpage52
dc.identifier.issn1128-3602
dc.identifier.pmid37869947
dc.identifier.scopus2-s2.0-85175497074
dc.identifier.scopusqualityQ2
dc.identifier.startpage43
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24275
dc.identifier.volume27
dc.identifier.wosWOS:001091509100008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherVerduci Publisher
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectBiologics; Anti-IgE monoclonal antibody; Anti-IL-4/IL-13; Anti-IL-5; Omalizumab; Dupilumab; Mepolizumab; Reslizumab; Benralizumab
dc.titleBiologics in allergic rhinitis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin/Full Text
Boyut:
384.6 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu